CCRA (Clinical & Contract Research Association)
Supporting Life Science research contractors.
CCRA (Clinical & Contract Research Association)
Supporting Life Science research contractors.
About CCRA (Clinical & Contract Research Association)
All organizations that provide clinical and contract development services for the pharmaceutical and biotechnology sectors are represented by the Clinical & Contract Research Association (CCRA).
More in Clinical Research
Novavax, Inc.
A late-stage biotechnology business called Novavax, Inc. (Nasdaq: NVAX) works to advance global health by discovering, creating, and commercializing novel vaccines to fend off deadly infectious illnesses. Clinical studies are being conducted for NVX-CoV2373, a vaccine candidate by Novavax against COVID-19's causative virus, SARS-CoV-2. In the Phase 1 section of the Phase 1/2 clinical study, NVXCoV2373 was usually well tolerated and produced significant antibody responses that were quantitatively greater than those found in human convalescent sera. In its critical Phase 3 clinical study in older individuals, NanoFluTM, its quadrivalent influenza nanoparticle vaccine, achieved all major goals. Both vaccination candidates use Novavax's patented Matrix-MTM adjuvant, which is based on saponins and stimulates the production of large quantities of neutralizing antibodies. A renowned producer of recombinant vaccines, Novavax's
4MCS
With over 130 years of combined experience in clinical trials and the pharmaceutical sector, 4MCS is a company committed to enhancing patient quality of life. Throughout the length of the research, patients and their accompanying person can relax in a comfortable setting thanks to the professional training and friendliness of the team at 4MCS.
Adaptimmune
A biopharmaceutical business in the trial stages called Adaptimmune is dedicated to creating cutting-edge cancer immunotherapy medicines for cancer patients. T-cells may be engineered to target and eradicate cancer across a variety of solid tumours thanks to the company's exclusive SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell technology.
